Drug Information

Drug General Information
Drug ID
D01FUC
Former ID
DIB014573
Drug Name
Exatecan
Synonyms
Exatecan mesylate; DX-8951; DX-8951a; DX-8951f; UM-1; UM-2
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 3 [521494]
Company
Daiichi Seiyaku Co Ltd
Formula
C24H22FN3O4
Canonical SMILES
n12c(c3c(c4c5c(c(c(cc5n3)F)C)CC[C@@H]4N)C2)cc2c(c1=O)CO<br />C(=O)[C@]2(O)CC
PubChem Compound ID
151115
Target and Pathway
Target(s) Toposisomerase-1 Target Info Inhibitor [526228]
NetPath Pathway IL2 Signaling Pathway
PANTHER Pathway DNA replication
Pathway Interaction Database Caspase Cascade in Apoptosis
WikiPathways Integrated Pancreatic Cancer Pathway
References
Ref 521494ClinicalTrials.gov (NCT00023972) Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 526228Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.